Search for a clinical trial
Other search option(s)
29 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Terminated trial = 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
Institution: Information not provided - US
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors (Phase 2) - AT
Institution: Information not provided - AT
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
NIRVANA-1: Randomized Study of Paclitaxel-carboplatin Followed by Niraparib Compared to Paclitaxel-carboplatin-bevacizumab Followed by Niraparib+Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-line Complete Surgery - BE
Institution: Information not provided - BE
FRANCE
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
NIRVANA-1: Randomized Study of Paclitaxel-carboplatin Followed by Niraparib Compared to Paclitaxel-carboplatin-bevacizumab Followed by Niraparib+Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-line Complete Surgery -FR
CHU de Lyon HCL - GH Sud
Service d'oncologie médicale
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
AGO-OVAR 2.29: Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial - DE
Institution: Information not provided - DE
ISRAEL
ISRAEL
ADDRESS: NOT PROVIDED - IL
A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer -IL
Institution: Information not provided - IL
ITALY
EMILIA ROMAGNA
BOLOGNA
A randomized, phase III trial of Patupilone vs Pegylated Liposomal Doxorubicin in Taxane in patients with recurrent epithelial ovarian, primary fallopian or primary peritoneal cancer
IRCCS Policlinico Sant'Orsola
S.S.D. Oncologia Medica
NETHERLANDS
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
ROSY-O: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
NIRVANA-1: Randomized Study of Paclitaxel-carboplatin Followed by Niraparib Compared to Paclitaxel-carboplatin-bevacizumab Followed by Niraparib+Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-line Complete Surgery -ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer -ES
Institution: Information not provided - ES
UNITED KINGDOM
Greater London
LONDON
SOLO 2: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy - UK
UCLH Gynaecological Cancer Centre, University College London
UCLH Gynaecological Cancer Centre, Women's Health Office Wing, 2nd Floor, North Wing
UNITED KINGDOM
Greater London
LONDON
A Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimens - UK
UCLH Gynaecological Cancer Centre, University College London
UCLH Gynaecological Cancer Centre, Women's Health Office Wing, 2nd Floor, North Wing
UNITED KINGDOM
Lothian
EDINBURGH
SOLO 1: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy - UK
Western General Hospital
Edinburgh Cancer Research Centre
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma - IT
Institution: Information not provided - IT
ITALY
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Institution: Information not provided - US
Multinational clinical trial(s)
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA).
Institution: Information not provided - US
FRANCE
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
NIRVANA-1: Randomized Study of Paclitaxel-carboplatin Followed by Niraparib Compared to Paclitaxel-carboplatin-bevacizumab Followed by Niraparib+Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-line Complete Surgery.
CHU de Lyon HCL - GH Sud
Service d'oncologie médicale
NORWAY
Østlandet
ADDRESS: NOT PROVIDED - NO
Phase 1b, Multicentre, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Patients
Institution: Information not provided - NO
SWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy
Institution: Information not provided - SE
SWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy
Institution: Information not provided - SE
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer.
Institution: Information not provided - CH
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
ROSY-O: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1)
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US